Analysts think EXEL stock price could increase by 12%
Feb 05, 2026, 12:25 PM
-2.56%
What does EXEL do
Exelixis, an oncology company based in Alameda, California, focuses on developing treatments for difficult-to-treat cancers, with four marketed products including cabozantinib for various cancers. Founded in 2000, it employs 1,310 people.
20 analysts think EXEL stock price will increase by 12.43%. The current median analyst target is $47.94 compared to a current stock price of $42.64. The lowest analysts target is $30.30 and the highest analyst target is $63.00.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.